Blocknomi
Key Highlights The INTerpath-001 Phase 3 study successfully achieved its primary recurrence-free survival goal in high-risk melanoma patients treated by Merck and Moderna A total of 1,137 patients with Stage…
Related articles
-
Goldman Sachs to gain bitcoin and ETH income ETFs in up to $2.25 billion Neos acquisition
The Block Published 12.08.2026 17:01
-
On Holding (ONON) Stock Plunges 13% as Q2 Sales Fall Short of Forecasts
Blocknomi Published 11.08.2026 09:46
-
Polymarket’s 20% CLARITY Act odds sit on a market one $100K trade could radically reprice
CryptoSlate Published 18.08.2026 09:40
-
Baltimore Takes Legal Action Against Kalshi and Polymarket Over Alleged Unlicensed Sports Wagering
Blocknomi Published 14.08.2026 07:06
-
XRP (XRP) Price: Holds Near $1 Ahead of White House Crypto Meeting
Blocknomi Published 19.08.2026 09:38
-
21+ Best Bitcoin & Crypto Casinos & Gambling Sites South Korea: Our Top Picks Ranked
Blocknomi Published 13.08.2026 07:55
-
Visa Widens Stablecoin Payouts via Zerohash Rails
Decrypt Published 05.08.2026 19:42
-
Michael Saylor’s Strategy sells another 1,690 BTC as USD reserve hits $4.65 billion
The Block Published 10.08.2026 12:09